Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

Participants completing the EFC6049 (HMR1726D/3001) study were given the opportunity to continue in the extension study; * participants receiving teriflunomide 7 mg or 14 mg were blindly maintained on the same dose of teriflunomide. * participants receiving placebo were randomized at a 1:1 ratio to teriflunomide 7 mg or 14 mg. The study period per participant was broken down as follows: * Double-blind treatment: up to a maximum of 288 weeks or until teriflunomide was commercially available in the country where participant lived, * Post-washout follow-up: 4 weeks after last treatment intake. No post-washout follow up if participant continued on teriflunomide treatment by obtaining its commercial form after end of the study. The total duration of the extension was 292 weeks (about 6 years) from the first participant enrolled or until teriflunomide is commercially available in the country where participant lived.